Relapsed/refractory acute lymphoblastic leukemia outcomes after second-generation anti-CD19 chimeric antigen receptor T cells and blinatumomab
| Reference . | T-cell engager . | Population . | Response . | CRS . | Neurologic toxicity . |
|---|---|---|---|---|---|
| Anti-CD19 CAR T cells | |||||
| 6 | Anti-CD19 CAR T | N = 30 (r/rALL) | CR = 90% | 100% CRS | 43% total |
| CD3z-4-1BB | Pediatric and adults | 27% severe | Encephalopathy | ||
| Aphasia | |||||
| Seizure (1) | |||||
| 1 | Anti-CD19 CAR T | N = 16 (r/rALL) | CR = 88% | 43% severe | 25% grade 3-grade 4 |
| CD3z-CD28 | Adults | Encephalopathy | |||
| Seizure | |||||
| 3 | Anti-CD19 CAR T | N = 21 (r/rALL) | CR = 67% | 76% CRS | 29% total |
| CD3z-CD28 | Pediatric and young adults | 28% severe | Hallucinations | ||
| Dysphasia | |||||
| Encephalopathy | |||||
| Blinatumomab | |||||
| 5 | Blinatumomab | N = 189 (r/rALL) | CR/CRh = 43% | 60% pyrexia | 52% total |
| Adults | 28% febrile neutropenia | 11% grade 3 | |||
| 2% grade 3 CRS | 2% grade 4 |
| Reference . | T-cell engager . | Population . | Response . | CRS . | Neurologic toxicity . |
|---|---|---|---|---|---|
| Anti-CD19 CAR T cells | |||||
| 6 | Anti-CD19 CAR T | N = 30 (r/rALL) | CR = 90% | 100% CRS | 43% total |
| CD3z-4-1BB | Pediatric and adults | 27% severe | Encephalopathy | ||
| Aphasia | |||||
| Seizure (1) | |||||
| 1 | Anti-CD19 CAR T | N = 16 (r/rALL) | CR = 88% | 43% severe | 25% grade 3-grade 4 |
| CD3z-CD28 | Adults | Encephalopathy | |||
| Seizure | |||||
| 3 | Anti-CD19 CAR T | N = 21 (r/rALL) | CR = 67% | 76% CRS | 29% total |
| CD3z-CD28 | Pediatric and young adults | 28% severe | Hallucinations | ||
| Dysphasia | |||||
| Encephalopathy | |||||
| Blinatumomab | |||||
| 5 | Blinatumomab | N = 189 (r/rALL) | CR/CRh = 43% | 60% pyrexia | 52% total |
| Adults | 28% febrile neutropenia | 11% grade 3 | |||
| 2% grade 3 CRS | 2% grade 4 |
NR, not reported.